ASO SS Antonio e Biagio e C Arrigo Alessandria, Italy Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2004
NCT00630747
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo | Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo | Azienda Ospedaliera SS Antonio e Biagio, Alessandria | Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo - Alessandria | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria | Ospedale S. S. Annunziata | Ospedale SS. Antonio, Biagio e Cesare Arrigo | S.O.C. di Ematologia, Azienda Ospedaliera SS Antonio e Biagio, Alessandria. Via Venezia 18 - 15100 - Alessandria | SS. Antonio e C. Arrigo Hospital Alessandria (Italy)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hodgkin Disease (Phase 3)

Lymphoma (Phase 3)

Mesothelioma (Phase 2)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis II (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Preleukemia (Phase 3)

Sarcoma (Phase 2)

Soft Tissue Neoplasms (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 14